Tag: Garetosmab-grts
-
Regeneron Wins FDA Approval for Pasatru in Ultra-Rare Bone Disease
The FDA approved Regeneron’s Pasatru for adults with fibrodysplasia ossificans progressiva after Phase 3 data showed a 90–94% reduction in new heterotopic ossification lesions versus placebo.